Product Code: GDHC119POA
Acute Lymphocytic Leukemia (ALL) is a rare blood malignancy that affects the bone marrow and peripheral blood and originates from either B- or T-cells. While high long term overall survival (OS) rates have been achieved with the use of chemotherapy in children, outcomes in adults are suboptimal and outcomes for patients with T-ALL specifically have always been dismal. Prior to 2015, the main treatment options comprised various chemotherapy regimens and tyrosine kinase inhibitors (TKIs) such as Novartis' Gleevec/Glivec (imatinib) or Bristol-Myers Squibb's Sprycel (dasatinib) for patients with Ph+ ALL.
The global market is expected to grow from $1.46B in 2019 to $2.26B in 2029 at a CAGR of 4.4%. The introduction of five new pipeline agents and label expansions for currently approved agents are key drivers of this market growth. Also, China moving away from generic chemotherapies and adopting more effective and premium-priced agents will contribute significantly to this market's expansion. However, the market value already shows signs of congestion and there are key patent expiries that will prohibit growth.
- The main drivers of growth include the anticipated approval and launch of five pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
- The main barriers to growth in the 8MM are key patent expiries of kinase inhibitors during the forecast period and a lack of industrial investment for niche patient populations such as T-ALL due to the low incidence of ALL.
- Among the late-stage pipeline products and marketed agents, CAR-T cell therapies and asparaginase enzymes are expected to generate the greatest revenues over the forecast period.
- The most important unmet needs in the ALL market include: Improved overall survival after relapse, replacement of the toxic stem cell transplant procedure and improved outcomes for T-ALL patients.
KEY QUESTIONS ANSWERED
- Five late-stage pipeline agents are expected to enter the Acute Lymphocytic Leukemia market from 2020 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
- What are the current unmet needs in Acute Lymphocytic Leukemia, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
- How has the introduction of Kymriah shaped the relapsed/refractory care? How will the competition fare?
- What is the expected future uptake of monoclonal antibodies in ALL across the 8MM?
- Overview of Acute Lymphocytic Leukemia including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline Acute Lymphocytic Leukemia market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Acute Lymphocytic Leukemia therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
- Analysis of the current and future market competition in the global Acute Lymphocytic Leukemia therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global Acute Lymphocytic Leukemia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Acute Lymphocytic Leukemia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global Acute Lymphocytic Leukemia therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Acute Lymphocytic Leukemia: Executive Summary
- 2.1 The Acute Lymphocytic Leukemia Market Will Grow at a 4.4% Rate During 2019-2029
- 2.2 Label Expansions and New CAR-T Cell Products Drive Improvements in Acute Lymphocytic Leukemia Care
- 2.3 Improved Overall Survival After Relapse and Stem Cell Transplant Replacements Remain Key Unmet Needs
- 2.4 CAR-T Cells Shape the Future of the Acute Lymphocytic Leukemia Market
- 2.5 What Do Physicians Think?
- 3.1 Catalyst
- 3.2 Related Reports
- 3.3 Upcoming Related Reports
4 Disease Overview
- 4.1 Etiology and Pathophysiology
- 4.1.1 Etiology
- 4.1.2 Pathophysiology
- 4.2 Classification and Subtypes
- 5.1 Disease Background
- 5.2 Risk Factors and Comorbidities
- 5.3 Global and Historical Trends
- 5.4 Forecast Methodology
- 5.4.1 Sources Used and Not Used
- 5.4.2 Forecast Assumptions and Methods
- 5.5 Epidemiological Forecast for ALL (2019-2029)
- 5.5.1 Diagnosed Incident Cases of ALL
- 5.5.2 Age-Specific Diagnosed Incident Cases of ALL
- 5.5.3 Sex-Specific Diagnosed Incident Cases of ALL
- 5.5.4 Diagnosed Incident Cases of B-Cell and T-Cell ALL
- 5.5.5 Five-Year Diagnosed Prevalent Cases of ALL
- 5.6 Discussion
- 5.6.1 Epidemiological Forecast Insight
- 5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
- 5.6.3 Limitations of the Analysis
- 5.6.4 Strengths of the Analysis
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Agents for T-ALL and Infant ALL
- 7.3 More Tolerable Curative Regimens
- 7.4 Improving Overall Survival After Relapse
- 7.5 Improved CAR-T Cells and HSCT Replacements
- 7.6 More Convenient Regimens
8 R&D Strategies
- 8.1 Overview
- 8.1.1 Label Expansions in Earlier Lines of Therapy
- 8.1.2 Improved CAR-T Cells
- 8.1.3 Improved Asparaginase Products
- 8.2 Clinical Trials Design
- 8.2.1 Flexible Criteria Based on the Patient Population and Unmet Need
- 8.2.2 Pharmacokinetics as the Critical Endpoint for Asparaginases
- 8.2.3 Significant Contribution of Public Funding
9 Pipeline Assessment
- 9.1 Overview
- 9.2 Innovative Early Stage Approaches
- 9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
- 10.1 Clinical Benchmark of Key Pipeline Drugs
- 10.2 Commercial Benchmark of Key Pipeline Drugs
- 10.3 Competitive Assessment
- 10.4 Top-Line 10-Year Forecast
- 10.4.1 US
- 10.4.2 5EU
- 10.4.3 Japan
- 10.4.4 China
List of Tables
List of Tables
- Table 1: Acute Lymphocytic Leukemia: Key Metrics in the 8MM
- Table 2: Classification of ALL Patients
- Table 3: Risk Factors and Comorbidities for ALL
- Table 4: Treatment Guidelines for ALL
- Table 5: Leading Treatments for ALL, 2019
- Table 6: Previous ALL Pivotal Trials with Their Respective Endpoints
- Table 7: Comparison of Therapeutic Classes in Development for ALL, 2019-2029
- Table 8: Innovative Early Stage Approaches for ALL, 2020
- Table 9: Drugs in Development for ALL, 2020
- Table 10: Clinical Benchmark of Key Marketed and Pipeline Drugs - ALL
- Table 11: Commercial Benchmark of Key Pipeline Drugs - ALL
- Table 12: Key Events Impacting Sales for ALL in the US, 2019-2029
- Table 13: ALL Market - Global Drivers and Barriers, 2019-2029
- Table 14: Key Historical and Projected Launch Dates for ALL
- Table 15: Key Historical and Projected Patent Expiry Dates for ALL
- Table 16: Most Commonly Used Regimens for ALL in the 8MM
- Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
List of Figures
- Figure 1: Global Sales Forecast by Country for Acute Lymphocytic Leukemia in 2019 and 2029
- Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Oncaspar Regimen and Blincyto
- Figure 3: Comparison of Normal and Leukemia Blood Cell Differentiation
- Figure 4: Agents Used to Target ALL Antigens/Pathways Specific to B- or T-cells
- Figure 5: 8MM, Diagnosed Incidence of ALL, Men and Women, All Ages, 2009-2019
- Figure 6: Sources Used to Forecast the Diagnosed Incident Cases of ALL
- Figure 7: Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of ALL
- Figure 8: 8MM, Diagnosed Incident Cases of ALL, Men and Women, All Ages, 2019
- Figure 9: 8MM, Diagnosed Incident Cases of ALL by Age Group, Men and Women, 2019
- Figure 10: 8MM, Diagnosed Incident Cases of ALL by Sex, All Ages, 2019
- Figure 11: 8MM, Diagnosed Incident Cases of B-cell and T-Cell ALL, Men and Women, All Ages, 2019
- Figure 12: 8MM, Five-Year Diagnosed Prevalent Cases of ALL, Men and Women, All Ages, 2019
- Figure 13: Current Treatment Algorithm of ALL
- Figure 14: Unmet Needs and Opportunities in ALL
- Figure 15: Overview of the ALL Development Pipeline
- Figure 16: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for ALL in the 8MM During the Forecast Period
- Figure 17: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Blincyto and Oncaspar Regimen
- Figure 18: Global (8MM) Sales Forecast by Country for ALL in 2019 and 2029
- Figure 19: Global Sales Forecast by Class for ALL in 2019 and 2029
- Figure 20: Sales Forecast by Class for ALL in the US in 2019 and 2029
- Figure 21: Sales Forecast by Class for ALL in the 5EU in 2019 and 2029
- Figure 22: Sales Forecast by Class for ALL in Japan in 2019 and 2029
- Figure 23: Sales Forecast by Class for ALL in China in 2019 and 2029